scholarly journals Strand Displacement Synthesis in the Central Polypurine Tract Region of HIV-1 Promotes DNA to DNA Strand Transfer Recombination

1996 ◽  
Vol 271 (47) ◽  
pp. 29605-29611 ◽  
Author(s):  
Gloria M. Fuentes ◽  
Chockalingam Palaniappan ◽  
Philip J. Fay ◽  
Robert A. Bambara
Biochemistry ◽  
1994 ◽  
Vol 33 (13) ◽  
pp. 3890-3895 ◽  
Author(s):  
James A. Peliska ◽  
Stephen J. Benkovic

2010 ◽  
Vol 84 (22) ◽  
pp. 11981-11993 ◽  
Author(s):  
Chunling Hu ◽  
Dyana T. Saenz ◽  
Hind J. Fadel ◽  
William Walker ◽  
Mary Peretz ◽  
...  

ABSTRACT HIV-1 and certain other retroviruses initiate plus-strand synthesis in the center of the genome as well as at the standard retroviral 3′ polypurine tract. This peculiarity of reverse transcription results in a central DNA “flap” structure that has been of controversial functional significance. We mutated both HIV-1 flap-generating elements, the central polypurine tract (cPPT) and the central termination sequence (CTS). To avoid an ambiguity of previous studies, we did so without affecting integrase coding. DNA flap formation was disrupted but single-cycle infection was unaffected in all target cells tested, regardless of cell cycle status. Spreading HIV-1 infection was also normal in most T cell lines, and flap mutant viruses replicated equivalently to the wild type in nondividing cells, including macrophages. However, spreading infection of flap mutant HIV-1 was impaired in non-vif-permissive cells (HuT78, H9, and primary human peripheral blood mononuclear cells [PBMCs]), suggesting APOBEC3G (A3G) restriction. Single-cycle infections confirmed that vif-intact flap mutant HIV-1 is restricted by producer cell A3G/F. Combining the Δvif and cPPT-CTS mutations increased A3G restriction synergistically. Moreover, RNA interference knockdown of A3G in HuT78 cells released the block to flap mutant HIV-1 replication. Flap mutant HIV-1 also accrued markedly increased A3G-mediated G→A hypermutation compared to that of wild-type HIV-1 (a full log10 in the 0.36 kb downstream of the mutant cPPT). We suggest that the triple-stranded DNA structure, the flap, is not the consequential outcome. The salient functional feature is central plus-strand initiation, which functions as a second line of defense against single-stranded DNA editing by A3 proteins that survive producer cell degradation by Vif.


Biochemistry ◽  
1994 ◽  
Vol 33 (46) ◽  
pp. 13817-13823 ◽  
Author(s):  
James A. Peliska ◽  
Shankar Balasubramanian ◽  
David P. Giedroc ◽  
Stephen J. Benkovic

Biochemistry ◽  
1999 ◽  
Vol 38 (40) ◽  
pp. 13070-13076 ◽  
Author(s):  
Sam Gabbara ◽  
Wendolyn R. Davis ◽  
Lynn Hupe ◽  
Donald Hupe ◽  
James A. Peliska

2008 ◽  
Vol 82 (15) ◽  
pp. 7716-7720 ◽  
Author(s):  
Mark Skasko ◽  
Baek Kim

ABSTRACT We tested whether the additional positive-strand DNA synthesis initiation of human immunodeficiency virus type 1 (HIV-1) from the central polypurine tract (cPPT) facilitates efficient completion of kinetically disturbed proviral DNA synthesis induced by dysfunctional reverse transcriptase (RT) mutants or limited cellular deoxynucleoside triphosphate (dNTP) pools. Indeed, the cPPT enabled the HIV-1 vectors harboring RT mutants with reduced dNTP binding affinity to transduce human lung fibroblasts (HLFs), without which these mutant vectors normally fail to transduce. The cPPT showed little effect on wild-type HIV-1 vector transduction in HLF, whereas it significantly enhanced vector transduction in HLFs engineered to contain reduced dNTP pools, suggesting a novel compensatory role for cPPT in viruses harboring kinetically impaired RT.


Virology ◽  
1992 ◽  
Vol 190 (1) ◽  
pp. 440-442 ◽  
Author(s):  
Olav Hungnesi ◽  
Enok Tjøtta ◽  
Bjørn Grinde

Viruses ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2501
Author(s):  
Steven J. Smith ◽  
Andrea Ferris ◽  
Xuezhi Zhao ◽  
Gary Pauly ◽  
Joel P. Schneider ◽  
...  

Integrase strand transfer inhibitors (INSTIs) are a class of antiretroviral compounds that prevent the insertion of a DNA copy of the viral genome into the host genome by targeting the viral enzyme integrase (IN). Dolutegravir (DTG) is a leading INSTI that is given, usually in combination with nucleoside reverse transcriptase inhibitors (NRTIs), to treat HIV-1 infections. The emergence of resistance to DTG and other leading INSTIs is rare. However, there are recent reports suggesting that drug resistance mutations can occur at positions outside the integrase gene either in the HIV-1 polypurine tract (PPT) or in the envelope gene (env). Here, we used single round infectivity assays to measure the antiviral potencies of several FDA-approved INSTIs and non-nucleoside reverse transcriptase inhibitors (NNRTIs) against a panel of HIV-1 PPT mutants. We also tested several of our promising INSTIs and NNRTIs in these assays. No measurable loss in potency was observed for either INSTIs or NNRTIs against the HIV-1 PPT mutants. This suggests that HIV-1 PPT mutants are not able, by themselves, to confer resistance to INSTIs or NNRTIs.


1994 ◽  
Vol 22 (6) ◽  
pp. 1121-1122 ◽  
Author(s):  
Daria J. Hazuda ◽  
Jeffrey C. Hastings ◽  
Abigail L. Wolfe ◽  
Emilio A. Emini

Sign in / Sign up

Export Citation Format

Share Document